Skip to main content

Table 2 Statistical comparison of clinical features among molecular subtypes.

From: Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization

 

Subtype I

Subtype II

Subtype III

Subtype IV

Subtype V

Subtype VI

Fisher's exact test

 

N = 37

N = 34

N = 41

N = 81

N = 41

N = 93

p value

Age at diagnosis

            

< 50 yr

27

73.0%

16

47.1%

30

73.2%

54

66.7%

22

53.7%

54

58.1%

 

>= 50 yr

10

27.0%

18

52.9%

11

26.8%

27

33.3%

19

46.3%

39

41.9%

0.08

T stage

             

1

8

21.6%

4

11.8%

10

24.4%

16

19.8%

22

53.7%

41

44.1%

 

2

28

75.7%

23

67.6%

20

48.8%

56

69.1%

17

41.5%

44

47.3%

 

3

1

2.7%

5

14.7%

7

17.1%

5

6.2%

1

2.4%

7

7.5%

 

4

0

0.0%

2

5.9%

4

9.8%

4

4.9%

1

2.4%

1

1.1%

2.00E-05

N stage

             

0

20

54.1%

7

20.6%

16

39.0%

31

38.3%

20

48.8%

43

46.2%

 

1

10

27.0%

10

29.4%

8

19.5%

25

30.9%

12

29.3%

22

23.7%

 

2

4

10.8%

11

32.4%

11

26.8%

14

17.3%

7

17.1%

16

17.2%

 

3

3

8.1%

6

17.6%

6

14.6%

11

13.6%

2

4.9%

12

12.9%

0.26

Pos. Lym. Nodes

             

0

20

54.1%

6

17.6%

16

39.0%

31

38.3%

20

48.8%

43

46.2%

 

1-3

10

27.0%

10

29.4%

8

19.5%

26

32.1%

12

29.3%

22

23.7%

 

4-9

4

10.8%

11

32.4%

10

24.4%

13

16.0%

7

17.1%

16

17.2%

 

> = 10

3

8.1%

5

14.7%

6

14.6%

9

11.1%

2

4.9%

12

12.9%

0.30

M stage

             

0

36

97.3%

33

97.1%

40

97.6%

78

96.3%

41

100.0%

91

97.8%

 

1

1

2.7%

1

2.9%

1

2.4%

3

3.7%

0

0.0%

2

2.2%

0.94

TNM Stage

             

I

6

16.2%

2

5.9%

10

24.4%

9

11.1%

12

29.3%

28

30.1%

 

II

23

62.2%

13

38.2%

11

26.8%

46

56.8%

18

43.9%

36

38.7%

 

II

6

16.2%

18

52.9%

19

46.3%

23

28.4%

10

24.4%

27

29.0%

 

IV

1

2.7%

1

2.9%

1

2.4%

3

3.7%

0

0.0%

2

2.2%

7.60E-04

Nuclear Grade

             

1

1

2.7%

0

0.0%

2

4.9%

2

2.5%

9

22.0%

17

18.3%

 

2

3

8.1%

1

2.9%

4

9.8%

11

13.6%

18

43.9%

38

40.9%

 

3

30

81.1%

28

82.4%

33

80.5%

62

76.5%

10

24.4%

33

35.5%

0

ER*

             

positive

0 (2)

0.0% (5%)

1 (6)

2.9% (20.6%)

10 (13)

24.4% (36%)

70 (66)

86.4% (90.4%)

41 (36)

100.0% (97.2%)

82 (75)

88.2% (91.5%)

 

negative

37 (34))

100.0% (95%)

33 (23)

97.1% (79.4%)

31 (23)

75.6% (64%)

11 (7)

13.6% (9.6%)

0 (1)

0.0% (2.8%)

11 (7)

11.8% (8.5%)

6.31E-51

HER2*

             

positive

4 (2)

10.8% (11.8%)

26 (9)

76.5% (81.8%)

18 (16)

43.9% (66.7%)

22 (11)

27.2% (33.3%)

0 (2)

0.0% (13.3%)

5 (7)

5.4% (15.9%)

 

negative

33 (17)

89.2% (88.2%)

8 (2)

23.5% (18.2%)

23 (8)

56.1% (33.3%)

59 (22)

72.8% (66.7%)

41 (13)

100.0% (86.7%)

88 (37)

94.6% (84.1%)

9.09E-20

PR*

             

positive

19 (9)

51.4% (25%)

14 (11)

41.2% (37.9%)

23 (16)

56.1% (44.4%)

73 (64)

90.1% (87.7%)

41 (34)

100.0% (91.9%)

88 (70)

94.6% (85.4%)

 

negative

18 (27)

48.6% (75%)

20 (18)

58.8% (62.1%)

18 (20)

43.9% (55.6%)

8 (9)

9.9% (12.3%)

0 (3)

0.0% (8.1%)

5 (12)

5.4% (14.6%)

2.26E-18

Local Relapse

             

No

31

83.8%

27

79.4%

39

95.1%

68

84.0%

34

82.9%

86

92.5%

 

Yes

6

16.2%

4

11.8%

1

2.4%

8

9.9%

3

7.3%

6

6.5%

0.29

Regional Relapse

             

No

32

86.5%

26

76.5%

37

90.2%

67

82.7%

36

87.8%

84

90.3%

 

Yes

2

5.4%

5

14.7%

3

7.3%

6

7.4%

1

2.4%

8

8.6%

0.54

Distant metastasis

             

No

31

83.8%

15

44.1%

33

80.5%

50

61.7%

39

95.1%

70

75.3%

 

Yes

6

16.2%

16

47.1%

8

19.5%

29

35.8%

2

4.9%

22

23.7%

2.51E-05

  1. *: Numbers in parentheses are results determined by immunohistochemistry. For HER2, 3+ was regarded as positive. P values for ER, HER2 and PR by IHC among all six molecular subtypes were 3 × 10-36, 2 × 10-4 and 1.4 × 10-14, respectively.